Microcap Ledger Entera Bio Ltd. $ENTX
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Capital Market
- Sector
- Biological Products, (No Diagnostic Substances)
- Headquarters
- Jerusalem
- Fiscal year end
- December 31
- Shares outstanding
- 173,141,831 [10-Q 2026-08-07]
What the company doesAI summary of filing
Entera Bio Ltd. is a clinical-stage biopharmaceutical company developing oral tablet formulations of peptides and protein replacement therapies for chronic conditions. The company's proprietary N-Tab platform is designed to stabilize and promote absorption of peptides in the gastrointestinal tract. Its most advanced program, EB613, is an oral PTH(1-34) tablet for postmenopausal osteoporosis currently in Phase 3 development; EB612 is an oral PTH tablet for hypoparathyroidism in early-stage development; and the company is collaborating with OPKO on oral GLP-1/Glucagon and oral GLP-2 programs for metabolic and gastrointestinal disorders, respectively. Entera is pre-revenue and does not generate product sales. [10-K 2026-03-27]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | $0.00 | −$10.82M | −$6.55M | $11.31M | [10-Q 2026-08-07] |
| FY ended Dec 2025 | $42.0K | −$11.44M | −$7.37M | $7.11M | [10-K 2026-03-27] |
| FY ended Dec 2024 | $181.0K | −$9.54M | −$6.82M | $8.66M | [10-K 2026-03-27] |
- Quarterly cash burn
- −$3.28M
- Cash runway Estimate
- ~10.4 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-11-04 | 36,832,220 | [10-Q 2024-11-08] |
| 2025-03-20 | 45,420,676 | [10-K 2025-03-28] |
| 2025-05-05 | 45,452,167 | [10-Q 2025-05-09] |
| 2025-08-04 | 45,663,381 | [10-Q 2025-08-08] |
| 2025-11-10 | 45,857,242 | [10-Q 2025-11-14] |
| 2026-03-23 | 46,622,239 | [10-K 2026-03-27] |
| 2026-05-04 | 49,225,321 | [10-Q 2026-05-08] |
| 2026-08-03 | 173,141,831 | [10-Q 2026-08-07] |
- Shelf registration
- S-3 filed 2026-08-21; declared effective 2026-08-28 [S-3 2026-08-21]
Listing status
Current status: No Form 8-K Item 3.01 (listing notice) filings in the last 24 months, as of 2026-10-11.
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-08-07 | Rubin Steven D | grant | 19,117 | — | [4 2026-08-07] |
| 2026-08-07 | Malca Yonatan | grant | 22,815 | — | [4 2026-08-07] |
| 2026-08-07 | Taitel Haya | grant | 20,790 | — | [4 2026-08-07] |
| 2026-08-07 | Ellis Sean | grant | 20,034 | — | [4 2026-08-07] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-10-06 | 8-K | Director or officer change; Regulation FD disclosure |
| 2026-09-23 | PRE 14A | Proxy statement |
| 2026-08-28 | 424B3 | Prospectus or prospectus supplement |
| 2026-08-21 | S-3 | Registration statement |
| 2026-08-18 | 8-K | Regulation FD disclosure; Other events |
| 2026-08-07 | 10-Q | Quarterly report |
| 2026-08-07 | 8-K | Results of operations; Regulation FD disclosure |
| 2026-08-04 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-08-04 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-08-04 | 13D | Beneficial ownership report (5%+ holder) |
| 2026-08-04 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-08-04 | 13G | Beneficial ownership report (5%+ holder) |
Alerts for $ENTX
Email me when Entera Bio Ltd. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.